Coherus Bioscien. Stock
€1.15
Your prediction
Coherus Bioscien. Stock
Pros and Cons of Coherus Bioscien. in the next few years
Pros
Cons
Performance of Coherus Bioscien. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Coherus Bioscien. | -1.880% | 4.096% | -16.974% | -74.559% | -61.546% | -91.276% | -94.079% |
| Evolus Inc | 11.940% | 13.636% | 23.967% | 72.414% | 65.746% | 123.881% | - |
| Ardelyx Inc. | 1.210% | 12.579% | 6.313% | 33.302% | -1.522% | 427.037% | 18.843% |
| Brainstorm Cell | 3.380% | 10.135% | -7.211% | -77.973% | 8.186% | -90.668% | -93.228% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Coherus Biosciences, a player in the Biotechnology & Medical Research sector, reflect a company struggling to find its footing in a fiercely competitive industry. With significant losses indicated across multiple financial metrics, it is clear that challenges abound. However, certain aspects do present opportunities for potential recovery and growth. This analysis delves into the various dimensions of Coherus' financial standing, highlighting both the strengths and weaknesses that define its current position.
Pros:
Market Capitalization and Target Price: Coherus holds a market capitalization of approximately $163 million, which can be seen as substantial for a biotech firm. Additionally, the Wall Street target price of $25.71 indicates optimistic projections from analysts, signaling potential upside for investors if the company can overcome its financial challenges.
